Post-pubertal emergence of alterations in locomotor activity in STOP null mice

Synapse

Volumn 61, Issue 9, 2007, Pages 689-697

  Bégou, Mélina ^a,b,c   Brun, Philippe ^a,b,c,d   Bertrand, Jean Baptiste ^a,b,c   Job, Didier ^e   Schweitzer, Annie ^e   D'Amato, Thierry ^a,b,c,f   Saoud, Mohamed ^a,b,c,f   Andrieux, Annie ^e   Suaud Chagny, Marie Françoise ^a,b,c,d  

^a Institut Federatif des Neurosciences de Lyon   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d INSERM   (France)

^e CEA GRENOBLE   (France)

^f CENTRE HOSPITALIER LE VINATIER   (France)

Author keywords

Amphetamine; Microtubules; MK 801; Prodrome; Schizophrenia

Indexed keywords

AMPHETAMINE; DIZOCILPINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; LOCOMOTION; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; STRESS;

AGING; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; MALE; MICE; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; MOTOR ACTIVITY;

EID: 34547203071     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20409     Document Type: Article

References (50)

1. Adriani W, Laviola G. 2000. A unique hormonal and behavioral hyporesponsivity to both forced novelty and D-amphetamine in periadolescent mice. Neuropharmacology 39:334-346.
2. Al-Amin HA, Weinberger DR, Lipska BK. 2000. Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus. Behav Pharmacol 11:269-278.
3. Al-Amin HA, Shannon Weickert C, Weinberger DR, Lipska BK. 2001. Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus. Biol Psychiatry 49:528-539.
4. Andrieux A, Salin PA, Vernet M, Kujala P, Baratier J, Gory-Faure S, Bosc C, Pointu H, Proietto D, Schweitzer A, Denarier E, Klumperman J, Job D. 2002. The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev 16:2350-2364.
5. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, Gory-Faure S, Kujala P, Suaud-Chagny MF, Hone G, Job D. 2006. Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biol Psychiatry 60:1224-1230.
6. Bolanos CA, Glatt SJ, Jackson D. 1998. Subsensitivity to dopaminergic drugs in periadolescent rats: A behavioral and neurochemical analysis. Brain Res Dev Brain Res 111:25-33.
7. Bosc C, Cronk JD, Pirollet F, Watterson DM, Haiech J, Job D, Margolis RL. 1996. Cloning, expression, and properties of the microtubule-stabilizing protein STOP. Proc Natl Acad Sci USA 93:2125-2130.
8. Brandon NJ, Handford EJ, Schurov I, Rain JC, Pelling M, Duran-Jimeniz B, Camargo LM, Oliver KR, Beher D, Shearman MS, Whiting PJ. 2004. Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: Implications for schizophrenia and other major neurological disorders. Mol Cell Neurosci 25:42-55.
9. Brun P, Begou M, Andrieux A, Mouly-Badina L, Clerget M, Schweitzer A, Scarna H, Renaud B, Job D, Suaud-Chagny MF. 2005. Dopaminergic transmission in STOP null mice. J Neurochem 94:63-73.
10. Carboni G, Tueting P, Tremolizzo L, Sugaya I, Davis J, Costa E, Guidotti A. 2004. Enhanced dizocilpine efficacy in heterozygous reeler mice relates to GABA turnover downregulation. Neuropharmacology 46:1070-1081.
11. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. 2001. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annu Rev Pharmacol Toxicol 41:237-260.
12. Chambers RA, Taylor JR, Potenza MN. 2003. Developmental neurocircuitry of motivation in adolescence: A critical period of addiction vulnerability. Am J Psychiatry 160:1041-1052.
13. Chartoff EH, Heusner CL, Palmiter RD. 2005. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 30:1324-1333.
14. De Bellis MD, Keshavan MS, Beers SR, Hall J, Frustaci K, Masalehdan A, Noll J, Boring AM. 2001. Sex differences in brain maturation during childhood and adolescence. Cereb Cortex 11: 552-557.
15. Eastwood SL, Lyon L, George L, Andrieux A, Job D, Harrison PJ. Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol (in press).
16. Fradley RL, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS. 2005. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163:257-264.
17. Frantz K, Van Hartesveldt C. 1999a. The locomotor effects of MK801 in the nucleus accumbens of developing and adult rats. Eur J Pharmacol 368:125-35.
18. Frantz K, Van Hartesveldt C. 1999b. Locomotion elicited by MK801 in developing and adult rats: Temporal, environmental, and gender effects. Eur J Pharmacol 369:145-57.
19. Gainetdinov RR, Mohn AR, Caron MG. 2001. Genetic animal models: Focus on schizophrenia. Trends Neurosci 24:527-533.
20. Geyer MA, Moghaddam B. 2002. Animal models relevant to schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: The fifth generation of progress. New York: American College of Neuropsychopharmacology. pp 689-701.
21. Gourzis P, Katrivanou A, Beratis S. 2002. Symptomatology of the initial prodromal phase in schizophrenia. Schizophr Bull 28:415-429.
22. Harrison PJ, Eastwood SL. 2001. Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. Hippocampus 11:508-519.
23. Hayashi MA, Portaro FC, Bastos MF, Guerreiro JR, Oliveira V, Gorrao SS, Tambourgi DV, Sant'Anna OA, Whiting PJ, Camargo LM, Konno K, Brandon NJ, Camargo AC. 2005. Inhibition of NUDEL (nuclear distribution element-like)- oligopeptidase activity by disrupted-in-schizophrenia 1. Proc Natl Acad Sci USA 102:3828-3833.
24. Hoffman RE, McGlashan TH. 1997. Synaptic elimination, neurodevelopment, and the mechanism of hallucinated "voices" in schizophrenia. Am J Psychiatry 154:1683-1689.
25. Ida I, Asami T, Kuribara H. 1995. Inhibition of cocaine sensitization by MK-801, a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: Evaluation by ambulatory activity in mice. Jpn J Pharmacol 69:83-90.
26. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
27. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, Cooper TB, Carlsson A, Laruelle M. 2000. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia. Biol Psychiatry 48:627-640.
28. Klosterkotter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F. 2001. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158-164.
29. Kuribara H, Asami T, Ida I, Tadokoro S. 1992. Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice: Assessment by the coadministration with central-acting drugs. Jpn J Pharmacol 58:11-18.
30. Laruelle M. 2000. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res Brain Res Rev 31:371-384.
31. Lencz T, Smith CW, McLaughlin D, Auther A, Nakayama E, Hovey L, Cornblatt BA. 2006. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 59:863-871.
32. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. 2001. The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884-897.
33. Lipska BK. 2004. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29:282-286.
34. Lipska BK, Weinberger DR. 2000. To model a psychiatric disorder in animals: Schizophrenia as a reality test. Neuropsychopharmacology 23:223-239.
35. McNamara RK, Logue A, Stanford K, Xu M, Zhang J, Richtand NM. 2006. Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse 60:399-405.
36. Mimics K, Middleton FA, Lewis DA, Levitt P. 2001. Analysis of complex brain disorders with gene expression microarrays: Schizophrenia as a disease of the synapse. Trends Neurosci 24:479-486.
37. Morris JA, Kandpal G, Ma L, Austin CP. 2003. DISC1 (Disrupted-In- Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: Regulation and loss of interaction with mutation. Hum Mol Genet 12:1591-1608.
38. Niculescu M, Ehrlich ME, Unterwald EM. 2005. Age-specific behavioral responses to psychostimulants in mice. Pharmacol Biochem Behav 82:280-288.
39. Olney JW, Newcomer JW, Farber NB. 1999. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
40. Rujescu D, Bender A, Keck M, Hartmann AM, Ohl F, Raeder H, Giegling I, Genius J, McCarley RW, Moller HJ, Grunze H. 2006. A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: Molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 59:721-729.
41. Saoud M, d'Amato T, Gutknecht C, Triboulet P, Bertaud JP, Marie-Cardine M, Dalery J, Rochet T. 2000. Neuropsychological deficit in siblings discordant for schizophrenia. Schizophr Bull 26:893-902.
42. Shimizu H, Iwayama Y, Yamada K, Toyota T, Minabe Y, Nakamura K, Nakajima M, Hattori E, Mori N, Osumi N, Yoshikawa T. 2006. Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr Res 84:244-252.
43. Spear LP. 2000. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 24:417-463.
44. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K. 2002. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892.
45. Tenn CC, Fletcher PJ, Kapur S. 2005. A putative animal model of the "prodromal" state of schizophrenia. Biol Psychiatry 57:586-593.
46. Thompson JL, Pogue-Geile MF, Grace AA. 2004. Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms. Schizophr Bull 30:875-900.
47. Tsai G, Coyle JT. 2002. Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179.
48. Tzschentke TM, Schmidt WJ. 1997. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization. Behav Brain Res 84:99-107.
49. Walker EF. 1994. Developmentally moderated expressions of the neuropathology underlying schizophrenia. Schizophr Bull 20:453-480.
50. Wu J, Zou H, Strong JA, Yu J, Zhou X, Xie Q, Zhao G, Jin M, Yu L. 2005. Bimodal effects of MK-801 on locomotion and stereotypy in C57BL/6 mice. Psychopharmacology (Berl) 177:256-263.